A significant sector rotation is currently underway in equity markets, shifting investor capital away from the mega-cap technology stocks that dominated recent years towards more traditional value and cyclical segments. This trend, gaining significant momentum in 2025, sees sectors such as financial services, basic materials, healthcare, energy, and industrials outperforming,
Looking for the most active S&P500 stocks in today's session? Join us as we dive into the US markets on Friday and discover the stocks that are dominating the trading activity and setting the pace for the market.
Sen. Elizabeth Warren (D-Mass.) is sounding the alarm on President Donald Trump's attempts at overhauling leadership at the Centers for Disease Control and Prevention, warning of risks to public health.
The financial markets are witnessing a profound rebalancing act, shifting away from the long-standing dominance of a handful of mega-cap technology giants towards a broader, more diversified landscape. This pivotal moment, gaining significant momentum in mid-2025, sees cyclical stocks, small-cap companies, and sectors like materials, consumer discretionary, and financials gaining
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at branded pharmaceuticals stocks, starting with Pfizer (NYSE:PFE).
The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy consumption of AI data centers is putting unprecedented strain on power grids and catalyzing a new wave of investment across traditional and
FDA approves Pfizer, Moderna, and Novavax Covid vaccines for high-risk groups as emergency authorizations end and vaccines transition to full marketing.
The global economy is sailing into Q3 2025 with a blend of cautious optimism and persistent challenges. While a new tariff regime and elevated geopolitical tensions introduce elements of uncertainty, the underlying currents suggest continued, albeit slower, economic expansion, particularly within the United States. Investors are keenly watching the interplay
Contrary to a common assumption at this time, not every stock is priced too richly or poses too much risk. Several underappreciated and undervalued names are just waiting to be found.
The global economic landscape is currently undergoing a seismic shift, as the United States has aggressively implemented a series of new tariffs and trade policy changes throughout 2025. These actions have dramatically increased the average effective U.S. tariff rate to levels not seen in decades, triggering immediate and far-reaching
The Trump administration may remove COVID-19 vaccines from the U.S. market as RFK Jr.'s allies gain influence at HHS, with a new vaccine task force led by a known skeptic.
Powell’s dovish Jackson Hole remarks signal that the Fed could cut rates as early as September, with markets now pricing an 80% chance of a 25 bps cut.
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges.
However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.
Over the past six months, Zoetis’s shares (currently trading at $156.80) have posted a disappointing 7% loss, well below the S&P 500’s 8.6% gain. This might have investors contemplating their next move.
